by adrenoglomerulotropin, a lipid factor, obtained from pineal extracts. It selectively stimulates secretion of aldosterone. The secretion of aldosterone has a diurnal rhythm.Control of aldosterone release from the adrenal cortex:
The role of the renin–angiotensin system:Angiotensin is involved in regulating aldosterone and is the core regulator. Angiotensin II acts synergistically with potassium.The role of sympathetic nerves:Aldosterone production is also affected to one extent or another by nervous control which integrates the inverse of carotid artery pressure, pain, posture, and probably emotion (anxiety, fear, and hostility)(including surgical stress).The role of baroreceptors:Pressure in the carotid artery decreases aldosteroneThe role of the juxtaglomerular apparatus
The plasma concentration of potassium:The amount of aldosterone secreted is a direct function of the serum potassium as probably determined by sensors in the carotid artery.The plasma concentration of sodium:Aldosterone is a function of the inverse of the sodium intake as sensed via osmotic pressure.Miscellaneous regulation:ACTH, a pituitary peptide, also has some stimulating effect on aldosterone probably by stimulating deoxycorticosterone formation which is a precursor of aldosterone. Aldosterone is increased by blood loss, pregnancy, and possibly by other circumstances such as physical exertion, endotoxin shock, and burns.Aldosterone feedback:
Feedback by aldosterone concentration itself is of a non-morphological character (that is, other than changes in cell number or structure) and is relatively poor so that electrolyte feedback predominates in the short term. Pathophysiology
The genes encoding aldosterone synthase and 11β-hydroxylase are 95% identical and are close together on chromosome 8.
The interaction of digoxin and cancer has also been studied. Despite existence of numerous preclinical studies that investigated the anticancer effects of digoxin, there are no solid and conclusive results so far. Several studies have suggested that digoxin may have anticancer properties, others not.Digoxin, as a cardiac glycoside, has a chemical structure basically similar to that of estradiol. Digoxin has the ability to bind oestrogen receptors, and therefore it has been proposed that it might increase the risk of oestrogen-sensitive breast and uterine cancers. A large Danish study found a complicated picture, with slightly increased risk of breast cancer amongst women taking digoxin, but better prognostic features. The Nurses Health Study found a similar slight increase of risk.Digoxin inhibits the proliferation of many cancerous cell lines in vitro, but its relevance to cancer in vivo remains unclear. References
Further reading
External links
"Digoxin". Drug Information Portal. U.S. National Library of Medicine. Commonly used website to calculate empiric digoxin doses for medical purposes for heart problems